An NCI-designated Comprehensive Cancer Center
Edward Weng Wang Profile Photo

Edward Wenge Wang, M.D., Ph.D.

Medical Oncologist
Clinical Expertise
  • Gynecologic Oncology
  • Hematology - Oncology
  • HIPEC - Heated Intraoperative Peritoneal Chemotherapy
Assistant Professor, Department of Medical Oncology & Therapeutics Research

Clinical Teams

  • HIPEC - Heated Intraoperative Peritoneal Chemotherapy

Edward Wenge Wang, M.D., Ph.D., is an assistant professor in the department of Medical Oncology, specializing in gynecologic oncology.

Dr. Wang earned his undergraduate degree in medicine, followed by a Master of Science degree in immunology and a Ph.D. in tumor immunology, from Harbin Medical University in Harbin, China.  He completed postdoctoral research at Columbia University in New York, before moving to Philadelphia to serve as a Research Associate at the Howard Hughes Medical Institute, while also serving as Senior Research Investigator at the University of Pennsylvania. 

After a brief time as Director of Projects for the Cancer Institute at Penn State Hershey Medical Center, Dr. Wang successfully completed postgraduate training with an internship and residency in internal medicine at Mount Vernon Hospital in New York, and Banner-University Medical Center in Phoenix, Arizona, respectively. He completed his Hematology Oncology fellowship training at Penn State Hershey Medical College in Pennsylvania.

Dr. Wang has authored 35 scholarly articles and has been an invited lecturer at symposiums and conferences across the country.  His research interests include: molecular targeting of p53-dictated cell death pathways for cancer treatment; exploration of the mechanism of DNA interaction-mediated p53 activation; targeting death receptor trafficking and signaling to reverse TRAIL resistance; bringing TRAIL and agonist antibodies back to clinical trials; and clearance of MCL-1-mediated cell survival signals to facilitate cancer cell death induced by intrinsic or extrinsic apoptotic pathways.  In 2002, Dr. Wang received the AACR/AFLAC Scholar-in-Training Award at the American Association for Cancer Research Annual Meeting in San Francisco.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  1. Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ: Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review, Clin Genitourin Cancer 2015,
  2. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS: Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects, Sci Transl Med 2013, 5:171ra117
  3. Zhou L, El-Deiry W, Wang W, Ingram ME, Katz SI: Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma, Oncol Rep 2012, 28:883-888
  4. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS: Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer, Cancer Biol Ther 2011, 12:239-251
  5. Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS: FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy, Int J Oncol 2011, 39:91-100
  6. Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS: Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents, Cancer Biol Ther 2011, 12:229-238
  7. Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS: Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction, Cancer Biol Ther 2011, 12:335-348
  8. Chen F, Wang W, El-Deiry WS: Current strategies to target p53 in cancer, Biochem Pharmacol 2010, 80:724-730
  9. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A: The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors, Cancer Res 2010, 70:8233-8246
  10. McGovern PE, Christofidou-Solomidou M, Wang W, Dukes F, Davidson T, El-Deiry WS: Anticancer activity of botanical compounds in ancient fermented beverages (review), Int J Oncol 2010, 37:5-14
  11. Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS: Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes, Cancer Biol Ther 2009, 8:2194-2205
  12. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS: The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells, Cancer Biol Ther 2009, 8:2186-2193
  13. Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS: Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma, Cancer Biol Ther 2009, 8:2406-2416
  14. Bassett EA, Wang W, Rastinejad F, El-Deiry WS: Structural and functional basis for therapeutic modulation of p53 signaling, Clin Cancer Res 2008, 14:6376-6386
  15. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS: TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death, Cancer Biol Ther 2008, 7:2034-2038
  16. Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM: DR5 receptor mediates anoikis in human colorectal carcinoma cell lines, Cancer Res 2008, 68:909-917
  17. Lu C, Wang W, El-Deiry WS: Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73, Cancer Biol Ther 2008, 7:2039-2046
  18. Wang W, El-Deiry WS: Restoration of p53 to limit tumor growth, Curr Opin Oncol 2008, 20:90-96
  19. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death, Cancer Cell 2007, 12:66-80
  20. Yang W, Rozan LM, McDonald ER, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS: CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation, J Biol Chem 2007, 282:3273-3281
  21. Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS: Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling, Cancer Biol Ther 2006, 5:1408-1414
  22. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X: Critical role for Daxx in regulating Mdm2, Nat Cell Biol 2006, 8:855-862
  23. Wang W, Kim SH, El-Deiry WS: Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts, Proc Natl Acad Sci U S A 2006, 103:11003-11008
  24. Liu JJ, Wang W, Dicker DT, El-Deiry WS: Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin, Cancer Biol Ther 2005, 4:885-892
  25. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, El-Deiry WS: Acridine derivatives activate p53 and induce tumor cell death through Bax, Cancer Biol Ther 2005, 4:893-898
  26. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS: Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth, Cancer Cell 2004, 6:597-609
  27. Gruber PJ, Li Z, Li H, Worrad D, Huang B, Abdullah I, Wang W, El-Deiry W, Ferrari VA, Zhou R: In vivo imaging of MLC2v-luciferase, a cardiac-specific reporter gene expression in mice, Acad Radiol 2004, 11:1022-1028
  28. Wang W, El-Deiry WS: Targeting FOXO kills two birds with one stone, Chem Biol 2004, 11:16-18
  29. Wang W, El-Deiry WS: Targeting p53 by PTD-mediated transduction, Trends Biotechnol 2004, 22:431-434
  30. Wang W, El-Deiry WS: Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model, Cancer Biol Ther 2003, 2:196-202
  31. Wang W, Rastinejad F, El-Deiry WS: Restoring p53-dependent tumor suppression, Cancer Biol Ther 2003, 2:S55-63
  32. Wang W, Takimoto R, Rastinejad F, El-Deiry WS: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding, Mol Cell Biol 2003, 23:2171-2181
  33. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein, Cancer Biol Ther 2002, 1:47-55
  34. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J: An iron delivery pathway mediated by a lipocalin, Mol Cell 2002, 10:1045-1056
  35. Wang W, Li W, Ikeda Y, Miyagawa JI, Taniguchi M, Miyoshi E, Sheng Y, Ekuni A, Ko JH, Yamamoto Y, Sugimoto T, Yamashita S, Matsuzawa Y, Grabowski GA, Honke K, Taniguchi N: Ectopic expression of alpha1,6 fucosyltransferase in mice causes steatosis in the liver and kidney accompanied by a modification of lysosomal acid lipase, Glycobiology 2001, 11:165-174

View more publications

In The News